Company profile: Asceneuron

1.1 - Company Overview

Asceneuron

Headquarter: Switzerland

Founded: 20XX🔒

Employees: 100-500🔒

🌐 Website

Company description

Provider of small molecule drug discovery and therapeutics for neurodegenerative diseases, focusing on orphan tauopathies and Alzheimer’s disease. Portfolio includes ASN51, a clinical-stage O-GlcNAcase inhibitor targeting tau aggregation for Alzheimer’s, progressing into Phase II, and ASN90, an O-GlcNAcase inhibitor for PSP, licensed to Ferrer with completed Phase I.

Products and services

Small Molecule Drug Discovery: Small-molecule program that develops effective therapeutics for orphan tauopathies and Alzheimer’s disease, focusing on high unmet medical needs in neurodegenerative disorders
ASN51: Clinical-stage O-GlcNAcase inhibitor that targets tau aggregation for treating Alzheimer’s disease, currently progressing into Phase II clinical development
ASN90: Phase I–completed O-GlcNAcase inhibitor developed for treating progressive supranuclear palsy (PSP), licensed to Ferrer Pharmaceuticals.

Key contacts

🔒

Financial details

🔒

1.2 - Competitors and similar companies to Asceneuron

Avalo Therapeutics

HQ: United States Website

Description: Provider of clinical-stage biopharmaceutical therapies for immunologic, immuno-oncologic and rare genetic disorders, advancing treatments for rare and orphan diseases. Pipeline includes AVTX-009 (anti-IL-1β) for inflammatory diseases; quisovalimab (anti-LIGHT) for inflammatory conditions; AVTX-008 (BTLA agonist) for immune dysregulation; and AVTX-002 (anti-LIGHT) in Phase 2 for non-eosinophilic asthma, inflammatory bowel diseases, and COVID-19 acute respiratory distress syndrome.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Avalo Therapeutics company profile →

Shape Therapeutics

HQ: United States Website

Description: Provider of AI-enabled RNA therapeutics and gene therapy technologies, including the ShapeTX AI Engine for data-driven medicine development; RNA Medicines for discovery and design; RNAfix recruiting ADAR to recode RNA; RNAskip suppressor tRNA addressing premature stop codons; RNAswap smart-sensing vectors for tailored gene expression; and Precise Delivery engineered capsids for targeted RNA delivery.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Shape Therapeutics company profile →

Magstim

HQ: United Kingdom Website

Description: Provider of Transcranial Magnetic Stimulation (TMS) stimulators and packages for Magstim TMS therapy and neuromodulation research. Offers Magstim TMS Therapy for depression, StimGuide for precise TMS delivery, and Neurosign intraoperative nerve monitoring solutions. Provides installation, certification training, and dedicated engineering service and support. Magstim stimulators are used in the majority of published TMS research.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Magstim company profile →

Engrail

HQ: United States Website

Description: Provider of medicines for patients with life-limiting diseases of the nervous system.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Engrail company profile →

NLS Pharmaceutics

HQ: Switzerland Website

Description: Provider of clinical-stage drug development focused on neurobehavioral and neurocognitive disorders and their pharmacognosia, using a patient-centered, target-specific approach via collaborations with industry and academia. Products include Quilience, an extended-release mazindol for excessive daytime sleepiness and cataplexy in narcolepsy, and Nolazol, a controlled-release mazindol for ADHD.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full NLS Pharmaceutics company profile →

🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒

🔒 View all strategic buyers with complete profiles

Start Free Trial →

2.2 - Strategic buyer groups for Asceneuron

🔒

Buyer group 1: ████████ ████████

●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 2: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 3: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔓 Unlock all detailed buyer group breakdowns with complete company profiles

Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Asceneuron

Buyout Funds
50+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US buyout funds investing in Asceneuron's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe buyout funds in Asceneuron's sector and industry vertical
View Funds →

2.2 - Growth funds investing in similar companies to Asceneuron

Growth Equity Funds
40+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US growth equity funds investing in Asceneuron's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe growth equity funds investing in Asceneuron's sector and industry vertical
View Funds →

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Asceneuron

4.2 - Public trading comparable groups for Asceneuron

🔒

Comparable group 1: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 2: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 3: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Asceneuron

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA

🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Asceneuron

What does Asceneuron do?

Asceneuron is a provider of small molecule drug discovery and therapeutics for neurodegenerative diseases, focusing on orphan tauopathies and Alzheimer’s disease. Portfolio includes ASN51, a clinical-stage O-GlcNAcase inhibitor targeting tau aggregation for Alzheimer’s, progressing into Phase II, and ASN90, an O-GlcNAcase inhibitor for PSP, licensed to Ferrer with completed Phase I.

Who are Asceneuron's competitors?

Asceneuron's competitors and similar companies include Avalo Therapeutics, Shape Therapeutics, Magstim, Engrail, and NLS Pharmaceutics.

Where is Asceneuron headquartered?

Asceneuron is headquartered in Switzerland.

How many employees does Asceneuron have?

Asceneuron has 1,000 employees 🔒.

When was Asceneuron founded?

Asceneuron was founded in 2010 🔒.

What sector and industry vertical is Asceneuron in?

Asceneuron is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Asceneuron

Who are the top strategic acquirers in Asceneuron's sector and industry

Top strategic M&A buyers and acquirers in Asceneuron's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Asceneuron?

Top strategic M&A buyers groups and sectors for Asceneuron include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Asceneuron's sector and industry vertical

Which are the top PE firms investing in Asceneuron's sector and industry vertical?

Top PE firms investing in Asceneuron's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Asceneuron's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Asceneuron's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Asceneuron's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Asceneuron include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Asceneuron's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Asceneuron?

The key public trading comparables and valuation benchmarks for Asceneuron include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Asceneuron for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Asceneuron with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Asceneuron's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Asceneuron with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Asceneuron's' sector and industry vertical?

Access recent funding rounds and capital raises in Asceneuron's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Asceneuron

Start Free Trial Book a Demo